Study of TS-172 in people with reduced liver function
Treatments studied
Part of Digestive system clinical trials.
This study tests how an experimental drug (TS-172) is processed in the body by comparing people with mild to moderate liver disease to those with normal liver function. It may help doctors understand how to dose the drug safely for people with liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are of Japanese ethnicity and between 18 and 75 years old.
- You have chronic (long-term) liver disease that is mild to moderate (Child-Pugh Class A or B).
- If you do not have liver disease, you must have a body mass index (BMI) between 18.5 and 35.
- Your kidney function must be good enough (eGFR above 45 if you have liver disease, or above 60 if you have normal liver function).
- You have not had liver surgery or a liver transplant, and you have not had severe confusion related to liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, TS-172, to lower high phosphorus levels in people with kidney disease who are on hemodialysis. It looks at safety and effectiveness over a longer period.
This trial tests a new medicine called TS-172 for people with high phosphorus levels who are on hemodialysis. It aims to lower phosphorus levels and is taken along with your current phosphate binder medication.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study tests a new medicine for people with mild or moderate liver problems to see how the liver affects the drug in the body. It also includes people with normal liver function for comparison.
This study looks at how a new oral drug (HS-10241) is processed by the body in people with mild to moderate liver disease and in healthy people. It helps find the right dose and safety for future patients with liver problems.
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
Hear when a new Patients With Mild or Moderate Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.